Randomised controlled trial of a psychosocial digital health application to promote coping for caregivers of patients undergoing haematopoietic stem cell transplantation: A study protocol for the BMT-CARE app Journal Article


Authors: Willis, K. D.; Barata, A.; Freese, M.; Applebaum, A. J.; Nelson, A.; Traeger, L. N.; Horick, N. K.; Rabideau, D. J.; Temel, J. S.; Greer, J. A.; Jacobs, J. M.; El-Jawahri, A.
Article Title: Randomised controlled trial of a psychosocial digital health application to promote coping for caregivers of patients undergoing haematopoietic stem cell transplantation: A study protocol for the BMT-CARE app
Abstract: Introduction Caregivers of patients undergoing haematopoietic stem cell transplantation (HSCT) experience tremendous psychological distress before, during and after HSCT. However, few interventions are tailored to the protracted needs of these caregivers while considering scalability and accessibility. We previously developed an evidence-based intervention for caregivers of patients undergoing HSCT that improved quality of life (QOL), caregiving burden and mood. We have since adapted this clinician-delivered intervention into a self-administered, digital health application (BMT-CARE app) and are currently evaluating the effect of this intervention on QOL in caregivers of patients receiving HSCT. Methods and analysis The study design is a non-blinded randomised controlled trial of a digital health intervention for caregivers of patients undergoing HSCT at the Massachusetts General Hospital Cancer Center. We are enrolling and randomising 125 caregivers to receive the BMT-CARE app or usual care in a 1:1 assignment, stratifying by transplant type (autologous vs allogeneic). Caregivers assigned to the BMT-CARE app complete five self-guided modules designed to improve coping and stress management prior to and up to 60 days post-HSCT. The modules include interactive, gamified features and video vignettes to optimise engagement. Participants complete questionnaires at baseline and days 10, 60 and 100 post-HSCT. The primary outcome is comparison of QOL at day 60 post-HSCT. Secondary outcomes include caregiver burden, anxiety and depression symptoms, as well as post-traumatic stress symptoms. We are also exploring the usability of the BMT-CARE app to inform refinements prior to future testing. Ethics and dissemination The study is funded by the Leukemia and Lymphoma Society and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #22-634 v.1.5). The results of this study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be disseminated at scientific meetings and in peer-reviewed journals. Trial registration number NCT05709912; Pre-results. © Author(s) (or their employer(s)) 2025.
Keywords: adult; controlled study; major clinical study; quality of life; randomized controlled trial; psychology; randomized controlled trials as topic; hematopoietic stem cell transplantation; adaptation, psychological; cancer center; depression; hematologic malignancy; posttraumatic stress disorder; allogeneic hematopoietic stem cell transplantation; caregiver; anxiety; stress management; therapy; autologous hematopoietic stem cell transplantation; mental stress; stress, psychological; psychological adjustment; massachusetts; caregiver burden; caregivers; engagement; general hospital; randomized controlled trial (topic); coping; vignette; psychosocial intervention; humans; human; male; female; article; mobile applications; clinical trial protocol; mobile application; digital health
Journal Title: BMJ Open
Volume: 15
Issue: 4
ISSN: 2044-6055
Publisher: BMJ Publishing Group Ltd.  
Date Published: 2025-04-01
Start Page: e092371
Language: English
DOI: 10.1136/bmjopen-2024-092371
PUBMED: 40204300
PROVIDER: scopus
PMCID: PMC11979604
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Allison Joyce Applebaum
    191 Applebaum